Literature DB >> 14679102

Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes.

Zandong Yang1, Meng Chen, Lawrence B Fialkow, Justin D Ellett, Runpei Wu, Jerry L Nadler.   

Abstract

We investigated the signal transduction pathway of IL-12 and showed that lisofylline (LSF) inhibited the signal transducer and activator of transcription factor-4 (STAT4) activation. Interruption of IL-12-mediated STAT4 activation prevented autoimmune diabetes in NOD mice.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14679102     DOI： 10.1196/annals.1288.069

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  15 in total

Review 1.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

2.  12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet.

Authors:  Craig S Nunemaker; Meng Chen; Hong Pei; Sarah D Kimble; Susanna R Keller; Jeffrey D Carter; Zandong Yang; Kellie M Smith; Runpei Wu; Melissa H Bevard; James C Garmey; Jerry L Nadler
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-09       Impact factor: 4.310

3.  Disease Risk-Associated Genetic Variants in STAT1 and STAT4 Function in a Complementary Manner to Increase Pattern-Recognition Receptor-Induced Outcomes in Human Macrophages.

Authors:  Matija Hedl; Rui Sun; Clara Abraham
Journal:  J Immunol       Date:  2020-07-13       Impact factor: 5.422

4.  STAT4 polymorphisms and diabetes risk: a meta-analysis with 18931 patients and 23833 controls.

Authors:  Jian Yi; Xin Fang; Youyun Wan; Juan Wei; Jianjun Huang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

5.  Amelioration of type 1 diabetes following treatment of non-obese diabetic mice with INGAP and lisofylline.

Authors:  Sarah A Tersey; Jeffery D Carter; Lawrence Rosenberg; David A Taylor-Fishwick; Raghavendra G Mirmira; Jerry L Nadler
Journal:  J Diabetes Mellitus       Date:  2012-05-01

6.  Deletion of 12/15-lipoxygenase alters macrophage and islet function in NOD-Alox15(null) mice, leading to protection against type 1 diabetes development.

Authors:  Shamina M Green-Mitchell; Sarah A Tersey; Banumathi K Cole; Kaiwen Ma; Norine S Kuhn; Tina Duong Cunningham; Nelly A Maybee; Swarup K Chakrabarti; Marcia McDuffie; David A Taylor-Fishwick; Raghavendra G Mirmira; Jerry L Nadler; Margaret A Morris
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

7.  Different toll-like receptor stimuli have a profound impact on cytokines required to break tolerance and induce autoimmunity.

Authors:  Albert C C Lin; Dilan Dissanayake; Salim Dhanji; Alisha R Elford; Pamela S Ohashi
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

8.  Testing agents for prevention or reversal of type 1 diabetes in rodents.

Authors:  Christian W Grant; Catherine M Moran-Paul; Shane K Duclos; Dennis L Guberski; Guillermo Arreaza-Rubín; Lisa M Spain
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

9.  Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice.

Authors:  Elżbieta Wyska; Artur Świerczek; Krzysztof Pociecha; Katarzyna Przejczowska-Pomierny
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-08       Impact factor: 2.441

10.  Complement Activation and STAT4 Expression Are Associated with Early Inflammation in Diabetic Wounds.

Authors:  Kenji M Cunnion; Neel K Krishna; Haree K Pallera; Angela Pineros-Fernandez; Magdielis Gregory Rivera; Pamela S Hair; Brittany P Lassiter; Ryan Huyck; Mary A Clements; Antoinette F Hood; George T Rodeheaver; Patrick S Cottler; Jerry L Nadler; Anca D Dobrian
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.